Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple
tumours. However, only a few patients respond to ICIs, which has generated considerable …

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to
inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite …

KRAS mutations are among the most common genetic alterations in lung, colorectal, and
pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit …

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway.
Concomitant mutations in both KRAS and BRAF genes have been identified in non-small …

Upregulated expression of immune checkpoint molecules correlates with exhausted
phenotype and impaired function of cytotoxic T cells to evade host immunity. By disrupting …

Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

Recently developed KRASG12C inhibitory drugs are beneficial to lung cancer patients
harboring KRASG12C mutations, but drug resistance frequently develops. Because of the …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

Over the past decade, RAS oncogenic proteins have transitioned from being deemed
undruggable to having two clinically approved drugs, with several more in advanced stages …